Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369811 | 1.00 | CCR4 (1.00) | CCR4 | |
| SCHEMBL1968579 | 0.91 | CCR4 (0.83) | CCR4 | |
| SCHEMBL1967107 | 0.91 | CCR4 (1.00) | CCR4 | |
| SCHEMBL1967148 | 0.91 | CCR4 (0.83) | CCR4 | |
| SCHEMBL1972347 | 0.90 | CCR4 (0.81) | CCR4 | |
| SCHEMBL1732492 | 0.88 | CCR4 (1.00) | CCR4 | |
| SCHEMBL1732807 | 0.87 | CCR4 (0.83) | CCR4 | |
| SCHEMBL1731814 | 0.87 | CCR4 (1.00) | CCR4 | |
| SCHEMBL6848031 | 0.87 | CCR4 (0.80) | CCR4 | |
| SCHEMBL1732317 | 0.86 | CCR4 (1.00) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968951-B1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | claimed |
| US-20100144759-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| US-20080293742-A1 | Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-20210253705-A1 | METHODS AND AGENTS FOR TREATING ORGAN INJURY AND TRANSPLANT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-19 | — | — | US | disclosed |
| EP-1968951-B1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-20100144759-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144759-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144759-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20080293742-A1 | Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293742-A1 | Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293742-A1 | Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1968951-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007069978-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007069978-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253705-A1 | METHODS AND AGENTS FOR TREATING ORGAN INJURY AND TRANSPLANT REJECTION | CCR4, CCR1, CCR3 | CCR4 1/4885 |
| US-20080293742-A1 | Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 | CCR4, CCR1, CCR3 | CCR4 1/4885 |
| US-20100144759-A1 | NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 | CCR4, CCR1, CCR3 | CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.